UY33372A - ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?. - Google Patents
?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.Info
- Publication number
- UY33372A UY33372A UY0001033372A UY33372A UY33372A UY 33372 A UY33372 A UY 33372A UY 0001033372 A UY0001033372 A UY 0001033372A UY 33372 A UY33372 A UY 33372A UY 33372 A UY33372 A UY 33372A
- Authority
- UY
- Uruguay
- Prior art keywords
- compositions
- manufacture
- quinolina
- medicines
- understand
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 quinoline analog compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33302010P | 2010-05-10 | 2010-05-10 | |
| US40693010P | 2010-10-26 | 2010-10-26 | |
| US201161477263P | 2011-04-20 | 2011-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY33372A true UY33372A (es) | 2011-12-30 |
Family
ID=44072535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001033372A UY33372A (es) | 2010-05-10 | 2011-05-09 | ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8394829B2 (enExample) |
| EP (1) | EP2569285A1 (enExample) |
| JP (2) | JP5807058B2 (enExample) |
| AR (1) | AR081026A1 (enExample) |
| AU (1) | AU2011253203A1 (enExample) |
| CA (1) | CA2796826A1 (enExample) |
| NZ (1) | NZ603136A (enExample) |
| UY (1) | UY33372A (enExample) |
| WO (1) | WO2011143105A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ603136A (en) * | 2010-05-10 | 2014-11-28 | Gilead Sciences Inc | Bifunctional quinoline derivatives |
| AP2015008663A0 (en) | 2013-02-19 | 2015-08-31 | Pfizer | Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders |
| JP6532474B2 (ja) * | 2014-02-06 | 2019-06-19 | アッヴィ・インコーポレイテッド | ６−ヘテロアリールオキシ−および６−アリールオキシ−キノリン−２−カルボキシアミドならびにその使用 |
| JP6125467B2 (ja) * | 2014-06-16 | 2017-05-10 | 富士フイルム株式会社 | プリント注文受付機とその作動方法および作動プログラム |
| EP3172210B1 (en) | 2014-07-24 | 2020-01-15 | Pfizer Inc | Pyrazolopyrimidine compounds |
| SG11201700243YA (en) | 2014-08-06 | 2017-02-27 | Pfizer | Imidazopyridazine compounds |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN106554350B (zh) * | 2015-09-29 | 2019-12-20 | 四川海思科制药有限公司 | 具有β2激动活性的苯并杂环衍生物及其制法和应用 |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| CN112250557A (zh) * | 2020-10-23 | 2021-01-22 | 徐州工程学院 | 一种高效合成1,6-二烯-3-酮衍生物的方法 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
| US3885047A (en) | 1972-06-16 | 1975-05-20 | Mead Johnson & Co | Ocular hypotensive process employing dextrorotatory phenethanolamines |
| US4145542A (en) | 1974-06-13 | 1979-03-20 | Otsuka Pharmaceutical Co., Ltd. | 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| US4761421A (en) | 1985-05-08 | 1988-08-02 | Merck & Co., Inc. | Use of certain compounds in livestock food as growth promotants for better feed utilization and improved carcass composition |
| US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| GB9107196D0 (en) | 1991-04-05 | 1991-05-22 | Sandoz Ag | Improvements in or relating to organic compounds |
| WO1993000951A1 (en) | 1991-07-02 | 1993-01-21 | Inhale, Inc. | Method and device for delivering aerosolized medicaments |
| US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| DK0617610T3 (da) | 1991-12-18 | 1997-10-06 | Minnesota Mining & Mfg | Suspensionsaerosolformuleringer. |
| US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
| US5455252A (en) | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| DE59410119D1 (de) | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
| BR9604978A (pt) | 1995-04-14 | 1998-06-09 | Glaxo Wellcome Inc | Inalador com dose medida |
| US5728712A (en) | 1995-05-19 | 1998-03-17 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
| GB9523267D0 (en) | 1995-11-14 | 1996-01-17 | Sandoz Ltd | Organic compounds |
| WO1997044322A1 (en) | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
| NZ332341A (en) | 1996-05-20 | 2000-05-26 | Darwin Discovery Ltd | Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors |
| GB9712761D0 (en) | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
| US6069151A (en) | 1996-11-06 | 2000-05-30 | Darwin Discovery, Ltd. | Quinolines and their therapeutic use |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| CZ293735B6 (cs) | 1998-08-26 | 2004-07-14 | Smithkline Beecham Corporation | Farmaceutický prostředek pro léčbu plicní nemoci |
| US6262070B1 (en) | 1998-11-04 | 2001-07-17 | Darwin Discovery Ltd. | Heterocyclic compounds and their therapeutic use |
| US6329034B1 (en) | 1999-01-18 | 2001-12-11 | Roger L. Pendry | Label having tab member and methods for forming, applying and using the same |
| US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
| ATE294608T1 (de) | 1999-06-05 | 2005-05-15 | Innovata Biomed Ltd | Verabreichungsystem für medikamente |
| GB2353222B (en) | 1999-06-23 | 2001-09-19 | Cambridge Consultants | Inhalers |
| CA2715683A1 (en) | 1999-08-21 | 2001-03-01 | Nycomed Gmbh | Synergistic combination |
| GB9920839D0 (en) | 1999-09-04 | 1999-11-10 | Innovata Biomed Ltd | Inhaler |
| US6880555B1 (en) | 1999-10-12 | 2005-04-19 | Shl Medical Ab | Inhaler |
| GB9928265D0 (en) | 1999-12-01 | 2000-01-26 | Innovata Biomed Ltd | Inhaler |
| AU8030500A (en) | 1999-12-08 | 2001-06-18 | Qualcomm Incorporated | Monitoring user interaction with web advertisements |
| SE9904706D0 (sv) | 1999-12-21 | 1999-12-21 | Astra Ab | An inhalation device |
| US6410563B1 (en) | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| US7171965B2 (en) | 2000-02-01 | 2007-02-06 | Valois S.A.S. | Breath actuated dry powder inhaler and tape dose strip |
| CZ20023997A3 (cs) * | 2000-06-05 | 2003-05-14 | Altana Pharma Ag | Pyridazinonové deriváty |
| FR2813593B1 (fr) | 2000-09-07 | 2002-12-06 | Valois Sa | Dispositif de distribution de produit fluide de type multidose |
| GB0026647D0 (en) | 2000-10-31 | 2000-12-13 | Glaxo Group Ltd | Medicament dispenser |
| US6740666B2 (en) | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| ATE296630T1 (de) | 2001-06-27 | 2005-06-15 | Merck Frosst Canada Inc | Substituierte 8-arylchinoline als pde4-hemmer |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US7144896B2 (en) | 2002-03-18 | 2006-12-05 | Merck Frosst Canada Ltd. | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors |
| US6889690B2 (en) | 2002-05-10 | 2005-05-10 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
| EP1507754A1 (en) * | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
| ATE356808T1 (de) | 2002-06-25 | 2007-04-15 | Merck Frosst Canada Ltd | 8-(biaryl)chinolin-pde4-inhibitoren |
| AU2003286024A1 (en) | 2002-11-22 | 2004-06-18 | Daniel Dube | Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
| US6903105B2 (en) | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| JP2006524638A (ja) | 2003-04-30 | 2006-11-02 | メルク フロスト カナダ リミテツド | ８−（３−ビアリール）フェニルキノリン系ホスホジエステラーゼ−４阻害薬 |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| EP1488819A1 (en) | 2003-06-16 | 2004-12-22 | Rijksuniversiteit te Groningen | Dry powder inhaler and method for pulmonary inhalation of dry powder |
| SI1663235T1 (sl) | 2003-08-18 | 2013-12-31 | Parion Sciences, Inc. | Zaščiteni pirazinoilgvanidinski blokatorji natrijevega kanala |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| GB0322726D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| WO2006023460A2 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| US7399766B2 (en) | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| GB0503955D0 (en) | 2005-02-25 | 2005-04-06 | Glaxo Group Ltd | Novel compounds |
| AU2006275137A1 (en) * | 2005-08-01 | 2007-02-08 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation |
| US7807834B2 (en) | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| US20100004215A1 (en) | 2005-10-19 | 2010-01-07 | Abhijit Ray | Compositions of phosphodiesterase type iv inhibitors |
| EP1981483A1 (en) | 2006-01-24 | 2008-10-22 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
| JP2009118740A (ja) | 2006-03-03 | 2009-06-04 | Ajinomoto Co Inc | Ｌ−アミノ酸の製造法 |
| GB0605462D0 (en) | 2006-03-17 | 2006-04-26 | Glaxo Group Ltd | Novel compounds |
| MX2008011963A (es) * | 2006-03-20 | 2008-10-01 | Pfizer Ltd | Derivados de amina. |
| PL2035004T3 (pl) | 2006-06-09 | 2013-01-31 | Parion Sciences Inc | Podstawione fenylem pirazynoiloguanidynowe blokery kanału sodowego o aktywności beta-agonistycznej |
| WO2008006050A2 (en) | 2006-07-07 | 2008-01-10 | Govek Steven P | Bicyclic heteroaryl inhibitors of pde4 |
| CN103784408A (zh) | 2007-07-24 | 2014-05-14 | 安迅生物制药公司 | 用于制备微粒的技术 |
| WO2009100169A1 (en) | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Dual pharmacophores - pde4-muscarinic antagonistics |
| WO2009142589A1 (en) | 2008-05-20 | 2009-11-26 | Astrazeneca Ab | Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist |
| US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
| WO2010015792A1 (en) * | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| UY32521A (es) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Combinación para emplear en el tratamiento de enfermedades respiratorias |
| WO2011143106A1 (en) * | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bi - functional pyrazolopyridine compounds |
| NZ603136A (en) * | 2010-05-10 | 2014-11-28 | Gilead Sciences Inc | Bifunctional quinoline derivatives |
-
2011
- 2011-05-09 NZ NZ603136A patent/NZ603136A/en not_active IP Right Cessation
- 2011-05-09 CA CA2796826A patent/CA2796826A1/en not_active Abandoned
- 2011-05-09 US US13/103,577 patent/US8394829B2/en not_active Expired - Fee Related
- 2011-05-09 UY UY0001033372A patent/UY33372A/es not_active Application Discontinuation
- 2011-05-09 AR ARP110101593A patent/AR081026A1/es unknown
- 2011-05-09 WO PCT/US2011/035738 patent/WO2011143105A1/en not_active Ceased
- 2011-05-09 EP EP11719748A patent/EP2569285A1/en not_active Withdrawn
- 2011-05-09 AU AU2011253203A patent/AU2011253203A1/en not_active Abandoned
- 2011-05-09 JP JP2013510204A patent/JP5807058B2/ja not_active Expired - Fee Related
-
2012
- 2012-09-14 US US13/619,636 patent/US20130012504A1/en not_active Abandoned
-
2015
- 2015-03-09 JP JP2015045538A patent/JP2015131833A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5807058B2 (ja) | 2015-11-10 |
| WO2011143105A1 (en) | 2011-11-17 |
| JP2013526520A (ja) | 2013-06-24 |
| EP2569285A1 (en) | 2013-03-20 |
| JP2015131833A (ja) | 2015-07-23 |
| NZ603136A (en) | 2014-11-28 |
| US20110275622A1 (en) | 2011-11-10 |
| AR081026A1 (es) | 2012-05-30 |
| AU2011253203A1 (en) | 2012-11-22 |
| CA2796826A1 (en) | 2011-11-17 |
| US8394829B2 (en) | 2013-03-12 |
| US20130012504A1 (en) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000008A1 (es) | Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| CR20150326A (es) | Inhibidores de autotaxina | |
| GT201500138A (es) | Novedososo derivados de bencimidazol como antagonistas de ep4 | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CO7240375A2 (es) | Compuestos tricíclicos sustituidos como inhibidores del fgfr | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| UY33776A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| CO7310531A2 (es) | 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos | |
| PE20150631A1 (es) | Formas cristalinas de un modulador del receptor androgenico | |
| UY33817A (es) | ?nuevas oxindolpirimidinas bencílicas?. | |
| GT201400085A (es) | Profármaco de adrenomedulina basado en polietilenglicol y su uso | |
| UY32629A (es) | Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c. | |
| AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
| UY33503A (es) | Imidazo [1,2-a]pirimidinas y piridinas sustituidas | |
| DOP2013000307A (es) | Antagonistas de trpv4 | |
| CL2014002505A1 (es) | Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos. | |
| CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
| NI201700052A (es) | Diamino-quinoleína 2,4 sustituida como nuevos agentes anticancerígenos | |
| DOP2015000076A (es) | Benzamidas | |
| CL2013000735A1 (es) | Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20200626 |